5
Claris Lifesciences
533288 BSE
Claris Lifesciences
Healthcare BSE: 533288 Pharmaceuticals & Biotechnology
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
1- Company has low interest coverage ratio.
Growth Rate
Net Income Growth
95% higher than
5Y
Quarterly Results
| Particulars | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 183 | 158 | 187 | 197 | 26 | 18 | 1 | 2 | 5 | 3 | 3 | 4 | 2 |
| Expenses | 136 | 134 | 141 | 184 | 65 | 39 | 16 | 27 | 39 | 21 | 22 | 16 | 375 |
| Operating Profit | 47 | 24 | 46 | 13 | -40 | -21 | -15 | -25 | -34 | -19 | -19 | -11 | -373 |
| OPM % | 26% | 15% | 25% | 6% | -155% | -114% | -1104% | -1411% | -752% | -676% | -611% | -264% | -18034% |
| Other Income | 27 | 14 | 8 | 21 | 33 | 17 | 40 | 56 | 44 | 53 | 38 | 1,865 | 59 |
| Interest | 11 | 10 | 10 | 11 | 1 | 2 | 1 | 4 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 9 | 10 | 4 | 1 | 1 | 2 | 0 | 1 | 2 | 1 | 1 | 1 |
| PBT | 53 | 18 | 34 | 18 | -8 | -7 | 22 | 27 | 8 | 32 | 17 | 1,852 | -316 |
| Tax % | -70% | 30% | 37% | 24% | -276% | -91% | 1% | -20% | -121% | -17% | -16% | 1% | 1% |
| Net Profit | 90 | 10 | 19 | 12 | -70 | -1 | 22 | 32 | 19 | 37 | 19 | 1,840 | -317 |
| EPS in Rs | 16.47 | 1.91 | 3.53 | 2.2 | -12.84 | -0.11 | 4.03 | 5.94 | 3.4 | 6.77 | 3.52 | 337 | -58.17 |
Profit & Loss
| Particulars | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 15m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 744 | 752 | 740 | 767 | 668 | 800 | 133 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 511 | 515 | 494 | 503 | 521 | 662 | 267 | 10.64 | 25.19 | 12.47 | 1.46 | 0.31 |
| Operating Profit | 233 | 237 | 246 | 265 | 146 | 138 | -134 | -10.64 | -25.19 | -12.47 | -1.46 | -0.31 |
| OPM % | 31.28% | 31.57% | 33.25% | 34.51% | 21.9% | 17.26% | -100.63% | — | — | — | — | — |
| Other Income | 9.23 | 16.46 | 15.33 | 10.29 | 78.76 | 104 | 80.99 | 120 | 42.57 | 7.63 | 0.46 | 0.04 |
| Interest | 53.26 | 46.75 | 55.43 | 65.05 | 52.19 | 48.26 | 5.48 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 44.81 | 46.72 | 54.68 | 74.27 | 65.35 | 49.05 | 3.86 | 0.14 | 0.1 | 0 | 0 | 0 |
| PBT | 144 | 160 | 151 | 136 | 107 | 144 | -62.35 | 109 | 17.28 | -4.84 | -1 | -0.27 |
| Tax % | 9.28% | 11.86% | 16.64% | 23.47% | 20.54% | -8.45% | -36.74% | -0.51% | 9.9% | 54.75% | 401% | 0% |
| Net Profit | 130 | 141 | 126 | 104 | 84.41 | 149 | -39.44 | 110 | 15.56 | -7.49 | -5.01 | -0.27 |
| EPS in Rs | — | 22.16 | 19.78 | 16.28 | 13.23 | 27.39 | -7.23 | 20.15 | 3.12 | -1.37 | -0.92 | -0.05 |
| Div. Payout % | 7.85% | 9.02% | 10.11% | 12.28% | 68.05% | 0% | -27.67% | 9.93% | 64.2% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 34.12 | 63.82 | 63.82 | 63.82 | 63.82 | 54.57 | 54.57 | 54.57 | 54.57 | 54.57 | 54.57 | 54.57 |
| Reserves | 476 | 851 | 988 | 1,085 | 1,340 | 1,262 | 865 | 965 | -53.86 | -60.94 | -65.96 | -66.23 |
| Borrowings | 314 | 361 | 409 | 542 | 268 | 534 | 599 | 21.56 | 0 | 0 | 20.97 | 21.01 |
| Other Liabilities | 532 | 419 | 270 | 311 | 439 | 333 | 229 | 741 | 23.31 | 28.1 | 0.4 | 0.43 |
| Total Liabilities | 1,356 | 1,695 | 1,731 | 2,002 | 2,111 | 2,184 | 1,747 | 1,782 | 24.02 | 21.73 | 9.98 | 9.78 |
| Fixed Assets | 492 | 531 | 663 | 871 | 572 | 1,074 | 866 | 56.41 | 0 | 0 | 0 | 0 |
| CWIP | 123 | 234 | 41.92 | 174 | 173 | 2.83 | 10.42 | 2.4 | 0 | 0 | 0 | 0 |
| Investments | 0.02 | 0.02 | 0.02 | 0.02 | 818 | 534 | 308 | 291 | 0 | 0 | 0 | 0 |
| Other Assets | 741 | 930 | 1,025 | 957 | 548 | 573 | 562 | 1,432 | 24.02 | 21.73 | 9.98 | 9.78 |
| Total Assets | 1,356 | 1,695 | 1,731 | 2,002 | 2,111 | 2,184 | 1,747 | 1,782 | 24.02 | 21.73 | 9.98 | 9.78 |
Cash Flow
| Particulars | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 381 | 69.67 | -18.93 | 334 | 143 | -41.43 | 20.46 | 179 | -5.82 | -0.15 | 6.17 | -0.11 |
| Investing | -104 | -192 | -221 | -437 | 197 | -123 | 56.8 | -58.46 | -133 | 0.35 | 0.41 | 0.05 |
| Financing | -56.95 | 281 | -24.2 | 58.27 | -343 | 152 | 22.28 | -105 | -13.14 | 0 | -6.67 | -0.01 |
| Net Cash Flow | 220 | 159 | -264 | -44.16 | -2.49 | -12.07 | 99.54 | 15.41 | -152 | 0.21 | -0.09 | -0.06 |
| Free Cash Flow | 279 | -126 | -253 | -109 | 924 | -259 | -90.95 | 109 | 3.18 | -0.15 | 6.17 | -0.11 |
| CFO/OP | 182 | 39 | -1 | 136 | 110 | 6 | -40 | -2,440 | 12 | 1 | -41 | 35 |
Ratios
| Particulars | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 130 | 120 | 135 | 109 | 85.55 | 105 | 459 | — | — | — | — | — |
| Inventory Days | 203 | 236 | 227 | 269 | 66.44 | 96.51 | 337 | — | — | — | — | — |
| Days Payable | 269 | 207 | 107 | 156 | 111 | 131 | 519 | — | — | — | — | — |
| Cash Conversion Cycle | 63.74 | 149 | 255 | 221 | 41.02 | 70.57 | 278 | — | — | — | — | — |
| Working Capital Days | 11.65 | 81.48 | 199 | 153 | -62.96 | 71.29 | 336 | — | — | — | — | — |
| ROCE % | 26.23% | 19.78% | 15.17% | 12.74% | 8.29% | 9.95% | -1.23% | 8.54% | 1.92% | — | -62.31% | -2.85% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Claris Lifesciences insights
65 extracted metrics + investor summaries across FY09–FY26.
Documents
1
Board Meeting Outcome for Composite Scheme Of Arrangement By And Amongst Mangalore Chemicals & Fertilizers Limited, Paradeep Phosphates Limited And Their Respective Shareholders And Creditors
16 Oct 2025 - Amalgamation effective 16 Oct 2025; appointed date 01 Apr 2024; record date 31 Oct 2025; 187:100 swap. 16 Oct 2025 - Amalgamation effective 16 Oct 2025; appointed date 01 Apr 2024; record date 31 Oct 2025; 187:100 swap.
2
31St October 2025 As The 'Record Date For The Purpose Of Composite Scheme Of Arrangement
16 Oct 2025 - Amalgamation effective Oct 16, 2025; Appointed Date Apr 1, 2024; Record Date Oct 31; 187:100 share swap. 16 Oct 2025 - Amalgamation effective Oct 16, 2025; Appointed Date Apr 1, 2024; Record Date Oct 31; 187:100 share swap.
3
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
14 Oct 2025 - Zuari sold 2,90,37,000 MCFL shares on 13 Oct 2025; stake falls from 54.03% to 29.53%. 14 Oct 2025 - Zuari sold 2,90,37,000 MCFL shares on 13 Oct 2025; stake falls from 54.03% to 29.53%.
5
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
13 Oct 2025 - NCLT-sanctioned composite scheme effective Oct 13, 2025; MCF to amalgamate into Paradeep; Effective Date2 Oct 16, 2025. 13 Oct 2025 - NCLT-sanctioned composite scheme effective Oct 13, 2025; MCF to amalgamate into Paradeep; Effective Date2 Oct 16, 2025.
Frequently Asked Questions about Claris Lifesciences
What does Claris Lifesciences Ltd do?
Claris Lifesciences Limited is engaged in manufacturing of drugs and pharmaceutical products.
Where is Claris Lifesciences Ltd (533288) listed?
Claris Lifesciences Ltd trades under code 533288 on the BSE.
Which sector does Claris Lifesciences Ltd belong to?
Claris Lifesciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Claris Lifesciences Limited is engaged in manufacturing of drugs and pharmaceutical products.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/533288.md for Claris Lifesciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.